P6.10 PROPIONYL-L-CARNITINE FOR INTERMITTENT CLAUDICATION. A COCHRANE REVIEW.

T. De Backer; V. Kamoen; R. Vander Stichele; L. Campens; D. De Bacquer; L. Van Bortel

doi:10.1016/j.artres.2014.09.161

<Previous Article In Issue

Download article (PDF)

Next Article In Issue>

Volume 8, Issue 4, December 2014, Pages 148 - 148

P6.10 PROPIONYL-L-CARNITINE FOR INTERMITTENT CLAUDICATION. A COCHRANE REVIEW.

Authors

T. De Backer^a^{, b}, V. Kamoen^b, R. Vander Stichele^a, L. Campens^b, D. De Bacquer^c, L. Van Bortel^a

^aHeymans Institute of Pharmacology, Ghent, Belgium

^bCardiovascular Center, Ghent, Belgium

^cDept of Epidemiology and Public Health, Ghent, Belgium

Available Online 4 November 2014.

DOI: 10.1016/j.artres.2014.09.161 How to use a DOI?
Open Access: This is an open access article distributed under the CC BY-NC license.

Intermittent claudication (IC) is a symptomatic form of peripheral arterial disease (PAD) (pain in the lower limbs with walking and relieved by rest). Propionyl-L-carnitine (PLC) is a drug which may lower the symptoms of PAD.

Is PLC efficacious in improving clinical outcomes in IC patients?

For this Cochrane review randomized controlled trials in patients with IC receiving PLC compared with placebo or other intervention were selected. Pain-free and maximal walking performance were analyzed by standardized exercise test. ABI, quality of life and adverse events were assessed. 13 Studies were included in this review (1423 patients). The results of the selected trials were brought together in patient pools. For the maximal walking distance, the mean difference in walking performance after use of PLC compared to placebo was an absolute increase of 50.86 m (95% CI 50.34 to 51.38) or a 26% relative improvement (23 to 28%). For the pain-free walking distance, the improvement in walking performance with PLC compared to placebo was an absolute increase of 32.98 m (32.60 to 33.37) or a 31 % relative improvement (28 to 34%) . PLCs had an 0.09 (0.08 to 0.09) improvement in ABI over placebo. The adverse events of PLC were similar as in the control group and PLC seemed well tolerated and safe. PLC 1-2g a day costs 0.30 to 0.70 €.

PLC for IC shows a significant, though mild to moderate improvement of walking distances and ABI compared to placebo. The safety of PLC is comparable to placebo. In practice, PLC could be useful adjuvant to classic IC-therapies or when these are contra-indicated, not feasible or ineffective.

This work is a Cochrane review. The data presented here presented are provisional (as the review has not yet been published).

The citation for the Cochrane protocol is: de Backer TLM, Campens L, Vander Stichele R, Van Bortel L, De Bacquer D. Propionyl-L-carnitine for intermittent claudication (Protocol). Cochrane Database of Systematic Reviews 2012, Issue 9. Art. No.: CD010117. DOI: 10.1002/14651858.CD010117.

The authors acknowledge the Cochrane Peripheral Vascular Diseases Group.

<Previous Article In Issue

Download article (PDF)

Next Article In Issue>

Journal: Artery Research
Volume-Issue: 8 - 4
Pages: 148 - 148
Publication Date: 2014/11/04
ISSN (Online): 1876-4401
ISSN (Print): 1872-9312
DOI: 10.1016/j.artres.2014.09.161 How to use a DOI?
Open Access: This is an open access article distributed under the CC BY-NC license.

Cite this article

ris enw bib

TY  - JOUR
AU  - T. De Backer
AU  - V. Kamoen
AU  - R. Vander Stichele
AU  - L. Campens
AU  - D. De Bacquer
AU  - L. Van Bortel
PY  - 2014
DA  - 2014/11/04
TI  - P6.10 PROPIONYL-L-CARNITINE FOR INTERMITTENT CLAUDICATION. A COCHRANE REVIEW.
JO  - Artery Research
SP  - 148
EP  - 148
VL  - 8
IS  - 4
SN  - 1876-4401
UR  - https://doi.org/10.1016/j.artres.2014.09.161
DO  - 10.1016/j.artres.2014.09.161
ID  - DeBacker2014
ER  -

download .riscopy to clipboard